Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following 2Seventy Bio’s recent announcement to be acquired by Bristol Myers (BMY). The firm expects an on-time transaction close in Q2 at the proposed transaction price.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSVT:
- Hold Rating Amidst Favorable Acquisition Terms and Competitive Pressures for 2seventy bio
- Spotify upgraded, Freshpet downgraded: Wall Street’s top analyst calls
- Morning Movers: 2seventy Bio skyrockets following acquisition by Bristol Myers
- 2seventy Bio downgraded to Market Perform from Outperform at Leerink
- 2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash